Related MeSH Hierarchy (7)
Diseases [C] » Urogenital Diseases [C12] » Genital Diseases » Genital Diseases, Male » Genital Neoplasms, Male » Prostatic Neoplasms
Diseases [C] » Urogenital Diseases [C12] » Genital Diseases » Genital Diseases, Male » Prostatic Diseases » Prostatic Neoplasms
Diseases [C] » Urogenital Diseases [C12] » Male Urogenital Diseases » Genital Diseases, Male » Genital Neoplasms, Male » Prostatic Neoplasms
Diseases [C] » Urogenital Diseases [C12] » Male Urogenital Diseases » Genital Diseases, Male » Prostatic Diseases » Prostatic Neoplasms
Diseases [C] » Urogenital Diseases [C12] » Male Urogenital Diseases » Urogenital Neoplasms » Genital Neoplasms, Male » Prostatic Neoplasms
Diseases [C] » Urogenital Diseases [C12] » Urogenital Neoplasms » Genital Neoplasms, Male » Prostatic Neoplasms
Diseases [C] » Neoplasms [C04] » Neoplasms by Site » Urogenital Neoplasms » Genital Neoplasms, Male » Prostatic Neoplasms
Hierarchy View
Subtype Terms (1)
Prostatic Neoplasms, Castration-Resistant
347 drugs (143 approved, 204 experimental)
Approved Indicated Drugs (38)
Phase 2 Indicated Drugs (373)
adenoviral vector expressing hsv-tk
autologous hematopoietic stem cells
bis-choline tetrathiomolybdate
dl-2-(difluoromethyl) ornithine
fowlpox-prostate specific antigen vaccine
her2bi-armed activated t cells
human choriogonadotropin alfa (hCG)
human fecal microbiota (Reybota)
hyaluronidase (human recombinant) (Hylenex)
hydroxychloroquine (plaquenil)
lu177 monoclonal antibody j591
lutetium dotatate lu-177 (Lutathera)
modified vaccinia ankara-5t4 vaccine
mrna from psa, pap, survivin and htert transfected dendritic cell
multi-valent pneumococcal conjugate vaccine
n-(4-hydroxyphenyl)all-trans retinamide
n-acetyl-s-(1,2-dichlorovinyl)-l-cysteine
phentolamine mesylate (regitine)
prostate specific membrane antigen
Phase 1 Indicated Drugs (223)
allogeneic adipose derived mesenchymal stem cell
autologous anti-psca-car-4-1bb/tcrzeta-cd19t-expressing t-lymphocytes
autologous dendritic cells transfected with amplified tumor rna
autologous natural killer cells
muc-2-globo h-klh conjugate vaccine
nkg2dl-targetting chimeric antigen receptor-grafted gamma delta t cell
Other Experimental Indicated Drugs (51)
Organization Involved with Phase 4 Indications (50)
Bay State Clinical Trials, Inc.
Canadian Urology Research Consortium
Chesapeake Urology Research Associates
International Drug Development Institute
National Cancer Institute (NCI)
Organization Involved with Phase 3 Indications (291)
ABX advanced biochemical compounds GmbH
ABX-CRO advanced pharmaceutical services Forschungsgesellschaft m.b.H.
Academic and Community Cancer Research United
Advanced Nuclear Medicine Ingredients
Amitabha Medical Clinic and Healing Center
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie (ARTIC)
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Australian National University
Badalona Hospital Germans Trias i Pujol
British Columbia Cancer Agency
Canadian Institutes of Health Research (CIHR)
Canadian Urologic Oncology Group
Cancer and Leukemia Group B (CALGB)
Cantonal Hospital of St. Gallen
Carolina Urologic Research Center
Case Western Reserve University
Central European Cooperative Oncology Group
Centre Catherine de Sienne - Nantes
Centre de Recherche Clinique du CHUS
Centre Georges Francois Leclerc
Centre hospitalier de Mulhouse
Centre Hospitalier de Saint-Brieuc
Deaconess Medical Center, Spokane, Washington
Eastern Cooperative Oncology Group
ECOG-ACRIN Cancer Research Group
European Organisation for Research and Treatment of Cancer
Foresee Pharmaceuticals Co., Ltd.
Groupe Hospitalier Paris Saint Joseph
Health Research Council, New Zealand
Herbert Irving Comprehensive Cancer Center
Hoosier Cancer Research Network
Hospital San Giacomo of Novi Ligure
Hospital Universitario Lucus Augusti
Icahn School of Medicine at Mount Sinai
Institut de Cancérologie de Lorraine
Institut de Cancerologie de l'Ouest Paul Papin
Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Katholieke Universiteit Leuven
Medicine Invention Design, Inc
Memorial Sloan-Kettering Cancer Center
Michael Reese Hospital and Medical Center
Molecular Insight Pharmaceuticals
National Cancer Institute, France
National Health and Medical Research Council, Australia
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
New Mexico Cancer Care Alliance
North Central Cancer Treatment Group
Oregon Health and Science University
Pan-American Medical Research Institute
Polyclinique d'oncologie de Gentilly, Nancy, France
Prostate Cancer Canada Network
Radiation Therapy Oncology Group
Radiological Associates of Sacramento Medical Group at Sutter Cancer Center
Royal Marsden Hospital NHS Trust
Saving Patients' Lives Medical B.V.
Scandinavian Prostate Cancer Group
Spanish Oncology Genito-Urinary Group
State University of New York, Buffalo
St. Luke's-Roosevelt Hospital Center
Swiss Group for Clinical Cancer Research
Technical University of Dresden
The University of Texas, Dallas
Tianjin University of Traditional Chinese Medicine
Translational Research Informatics Center, Kobe, Hyogo, Japan
Universidad Autonoma de Barcelona
Universidad Complutense de Madrid
Université catholique de Louvain
University of British Columbia
University of California, Davis
University of California, Los Angeles
University of California, San Francisco
University of Colorado, Denver
University of Illinois at Chicago
University of North Carolina, Charlotte
University of Southern California
Urology San Antonio Research PA
Organization Involved with Phase 2 Indications (411)
Adamis Pharmaceuticals Corporation
Advanced Accelerator Applications
Alexandra Hospital, Athens, Greece
All-Russia Centre for Urgent Care and Radiation Medicine
American Society of Clinical Oncology
Assistance Publique - Hôpitaux de Paris
Association of Urogenital Oncology (AUO)
Australasian Radiopharmaceutical Trials network
Australian Nuclear Science and Technology Organisation
Azienda Ospedaliera San Camillo Forlanini
Behnam Daheshpour Charity Organization, Tehran
Buckinghamshire Healthcare NHS Trust
Canadian Cancer Clinical Trials Network
Cancer Immunotherapy Trials Network
Cancer Therapeutics Research Group
Carolina Research Professionals, LLC
Cellular Biomedicine Group Ltd.
Central European Society for Anticancer Drug Research (CESAR)
Centre for Probe Development and Commercialization
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Chao Family Comprehensive Cancer Center
Chatrapati Sahuji Mahraj Medical University
Chinese Academy of Medical Sciences
Choithram Hospital and Research Centre
Christian Medical College, Vellore, India
City of Hope National Medical Center
Colchester Hospital University NHS Foundation Trust
Comprehensive Cancer Centers of Nevada
DanTrials ApS, Copenhagen, Denmark
Dartford and Gravesham NHS Foundation Trust
Desert Regional Comprehensive Cancer Center
East and North Hertfordshire NHS Trust
E-Group ICT Software Informatikai Zrt.
E.J. Whitten Foundation Prostate Cancer Research Centre
Excel Diagnostics and Nuclear Oncology Center
Frimley Park Hospital NHS Trust
Fundación Canaria de Investigación Sanitaria
GIRCI (French Interregional Group of Clinical Research and Innovation)
Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
Groupe D'Etude des Tumeurs Uro-Genitales
Guangdong Pharmaceutical University
Guangdong Provincial Hospital of Traditional Chinese Medicine
Hamilton Health Sciences Corporation
Health Ever Bio-Tech Co., Ltd.
Heatherwood and Wexham Park Hospitals NHS Foundation Trust
Hellenic Cooperative Oncology Group
High Impact Clinical Research Support Program
Hoag Memorial Hospital Presbyterian
Infinity Pharmaceuticals, Inc.
Institut Mutualiste Montsouris
Instituto do Cancer do Estado de São Paulo
Istituto Nazionale per lo Studio e la Cura dei Tumori
Italian Trial in Medical Oncology
Jahn Ferenc South Pest Hospital
James Graham Brown Cancer Center
Kidwai Memorial Institute of Oncology, Bangalore
Laboratoires Leurquin Mediolanum
Latin American Cooperative Oncology Group
Ligue Contre le Cancer (French association Against Cancer)
Maidstone & Tunbridge Wells NHS Trust
Medical Research Future Fund (MRFF)
Methodist Cancer Center, Houston, Texas
Moorgreen Hospital, Southampton
Morton Plant Mease Health Care
Moscow Oncology Research Institute
National Center for Complementary and Integrative Health (NCCIH)
National Comprehensive Cancer Network
National Health Service, United Kingdom
National Institute of Nursing Research (NINR)
National Institute on Aging (NIA)
National University of Ireland
National University of Singapore
Northern Sydney and Central Coast Area Health Service
North Middlesex University Hospital NHS Trust
Peachtree Hematology Oncology Consultants
Peterfy Sandor Street Hospital
Postgraduate Institute of Medical Education and Research
Prologue Research International
Prostate Cancer Clinical Trials Consortium
Prostate Cancer Foundation Norway
Prostate Cancer Foundation of Australia
Prostate Cancer Research Alliance
Radio Isotope Therapy of America
Rajiv Gandhi University of Health Sciences
Russian Academy of Medical Sciences
Seth Gordhandas Sunderdas Medical College
Smerud Medical Research Denmark
Southend University Hospital Foundation NHS Trust
St. Barnabas Medical Center, Livingston, NJ
St. Petersburg State Public Medical Institution
St. Vincent's Hospital-Manhattan
Suzhou Kintor Pharmaceutical Inc,
Sydney Haematology and Oncology Clinics
Taiwan Cooperative Oncology Group
The Adelaide and Meath Hospital
The European Uro-Oncology Group
The Prostate Cancer Research Foundation of Canada
The University of Texas Health Science Center, Houston
The Wayne D. Kuni and Joan E. Kuni Foundation
Translational Oncology Research International
Universidad Autonoma de Madrid
University of Alabama, Birmingham
University of California, Irvine
University of California, San Diego
University of Erlangen-Nuremberg
University of Las Palmas de Gran Canaria
University of Medicine and Dentistry of New Jersey
University of Naples Frederico II
University of Nice Sophia Antipolis
University of North Carolina at Chapel Hill
University of Technology, Sydney
Virginia Commonwealth University
Organization Involved with Phase 1 Indications (120)
Allife Medical Science and Technology Co., Ltd.
Biotech Equity Partners Pty Ltd
Cancer League of Colorado, Inc
Cancer Research Institute of Scott and White
Department of Radiation Oncology
Dizal (Jiangsu) Pharmaceutical Co., Ltd.
ImmunoVaccine Technologies, Inc.
Kangpu Biopharmaceuticals, Ltd
Memorial Hermann Health System
National Center for Research Resources (NCRR)
Northern Sydney Local Health District
Norwegian University of Life Sciences
Organization Involved with Other Experimental Indications (37)
Lotte & John Hecht Memorial Foundation
Medical Research Foundation, Oregon
Nikkei (Canada) Marketing Limited
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
